|
1
|
Becker MW and Jordan CT: Leukemia stem
cells in 2010: Current understanding and future directions. Blood
Rev. 25:75–81. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giles FJ, Keating A, Goldstone AH, Avivi
I, Willman CL and Kantarjian HM: Acute myeloid leukemia. Hematology
Am Soc Hematol Educ Program. 73–110. 2002.PubMed/NCBI
|
|
3
|
Chen J, Odenike O and Rowley JD:
Leukemogenesis: More than mutant genes. Nat Rev Cancer. 10:23–36.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vardiman JW, Harris NL and Brunning RD:
The World Health Organization (WHO) classification of the myeloid
neoplasms. Blood. 100:2292–2302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yates JW, Wallace HJ Jr, Ellison RR and
Holland JF: Cytosine arabinoside (NSC-63878) and daunorubicin
(NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer
Chemother Rep. 57:485–488. 1973.PubMed/NCBI
|
|
6
|
Slovak ML, Kopecky KJ, Cassileth PA,
Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR,
Rowe JM, et al: Karyotypic analysis predicts outcome of
preremission and postremission therapy in adult acute myeloid
leukemia: A southwest oncology group/eastern cooperative oncology
group study. Blood. 96:4075–4083. 2000.PubMed/NCBI
|
|
7
|
Grimwade D, Hills RK, Moorman AV, Walker
H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ and Burnett
AK: National Cancer Research Institute Adult Leukemia Working
Group: Refinement of cytogenetic classification in acute myeloid
leukemia: Determination of prognostic significance of rare
recurring chromosomal abnormalities among 5876 younger adult
patients treated in the United Kingdom medical research council
trials. Blood. 116:354–365. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grimwade D, Walker H, Harrison G, Oliver
F, Chatters S, Harrison CJ, Wheatley K, Burnett AK and Goldstone
AH: Medical Research Council Adult Leukemia Working Party: The
predictive value of hierarchical cytogenetic classification in
older adults with acute myeloid leukemia (AML): Analysis of 1065
patients entered into the United Kingdom medical research council
AML11 trial. Blood. 98:1312–1320. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Byrd JC, Mrózek K, Dodge RK, Carroll AJ,
Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS,
et al: Pretreatment cytogenetic abnormalities are predictive of
induction success, cumulative incidence of relapse and overall
survival in adult patients with de novo acute myeloid leukemia:
Results from cancer and leukemia group B (CALGB 8461). Blood.
100:4325–4336. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Walter RB, Kantarjian HM, Huang X, Pierce
SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS,
Appelbaum FR and Estey EH: Effect of complete remission and
responses less than complete remission on survival in acute myeloid
leukemia: A combined Eastern cooperative oncology group, southwest
oncology group and M. D. Anderson cancer center study. J Clin
Oncol. 28:1766–1771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jabbour EJ, Estey E and Kantarjian HM:
Adult acute myeloid leukemia. Mayo Clin Proc. 81:247–260. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grimwade D, Walker H, Oliver F, Wheatley
K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A and
Goldstone A: The importance of diagnostic cytogenetics on outcome
in AML: Analysis of 1,612 patients entered into the MRC AML 10
trial. The medical research council adult and children's leukemia
working parties. Blood. 92:2322–2333. 1998.PubMed/NCBI
|
|
13
|
Odenike O, Thirman MJ, Artz AS, Godley LA,
Larson RA and Stock W: Gene mutations, epigenetic dysregulation and
personalized therapy in myeloid neoplasia: Are we there yet? Semin
Oncol. 38:196–214. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bennet JM, Catovsky D, Daniel MT, Flandrin
G, Galton DA, Gralnick HR and Sultan C: Proposals for the
classification of the acute myeloid leukemias:
French-American-British cooperative group. Br J Hematol.
33:451–458. 1976. View Article : Google Scholar
|
|
15
|
British Committee for Standards in
Hematology; Milligan DW, Grimwade D, Cullis JO, Bond L, Swirsky D,
Craddock C, Kell J, Homewood J, Campbell K, et al: Guidelines on
the management of acute myeloid leukemia in adults. Br J Hematol.
135:450–474. 2006. View Article : Google Scholar
|
|
16
|
Wiernik PH, Banks PL, Case DC Jr, Arlin
ZA, Periman PO, Todd MB, Ritch PS, Enck RE and Weitberg AB:
Cytarabine plus idarubicin or daunorubicin as induction and
consolidation therapy for previously untreated adult patients with
acute myeloid leukemia. Blood. 79:313–319. 1992.PubMed/NCBI
|
|
17
|
Wiernik PH, Case DC Jr, Periman PO, Arlin
ZA, Weitberg AB, Ritch PS and Todd MB: A multicenter trial of
cytarabine plus idarubicin or daunorubicin as induction therapy for
adult nonlymphocytic leukemia. Semin Oncol. 16(1): Suppl 2.
S25–S29. 1989.
|
|
18
|
List AF, Spier C, Greer J, Wolff S, Hutter
J, Dorr R, Salmon S, Futscher B, Baier M and Dalton W: Phase I/II
trial of cyclosporine as a chemotherapy-resistance modifier in
acute leukemia. J Clin Oncol. 11:1652–1660. 1993.PubMed/NCBI
|
|
19
|
List AF, Kopecky KJ, Willman CL, Head DR,
Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, et
al: Benefit of cyclosporine modulation of drug resistance in
patients with poor-risk acute myeloid leukemia: A southwest
oncology group study. Blood. 98:3212–3220. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheson BD, Bennett JM, Kopecky KJ, Büchner
T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister
TA, et al: Revised recommendations of the international working
group for diagnosis, standardization of response criteria,
treatment outcomes and reporting standards for therapeutic trials
in acute myeloid leukemia. J Clin Oncol. 21:4642–4649. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Döhner H, Estey EH, Amadori S, Appelbaum
FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson
RA, et al: Diagnosis and management of acute myeloid leukemia in
adults: Recommendations from an international expert panel, on
behalf of the European LeukemiaNet. Blood. 115:453–474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gonzalez Garcia JR and Meza-Espinoza JP:
Use of the international system for human cytogenetic nomenclature
(ISCN). Blood. 108:3952–3953. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Clark GM: Prognostic factors versus
predictive factors: Examples from a clinical trial of erlotinib.
Mol Oncol. 1:406–412. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Clark GM, Zborowski DM, Culbertson JL,
Whitehead M, Savoie M, Seymour L and Shepherd FA: Clinical utility
of epidermal growth factor receptor expression for selecting
patients with advanced non-small cell lung cancer for treatment
with erlotinib. J Thorac Oncol. 1:837–846. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suvajdžić N, Cvetković Z, Dorđević V,
Kraguljac-Kurtović N, Stanisavljević D, Bogdanović A, Djunić I,
Colović N, Vidović A, Elezović I and Tomin D: Prognostic factors
for therapy-related acute myeloid leukemia (t-AML) - a single
centre experience. Biomed Pharmacother. 66:285–292. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Farag SS, Ruppert AS, Mrózek K, Mayer RJ,
Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR,
et al: Outcome of induction and postremission therapy in younger
adults with acute myeloid leukemia with normal karyotype: A cancer
and leukemia group B study. J Clin Oncol. 23:482–493. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Medeiros BC: Comparing apples and oranges
in normal karyotype acute myeloid leukemia. J Clin Oncol.
27:4742009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Christiansen DH and Pedersen-Bjergaard J:
Internal tandem duplications of the FLT3 and MLL genes are mainly
observed in atypical cases of therapy-related acute myeloid
leukemia with a normal karyotype and are unrelated to type of
previous therapy. Leukemia. 15:1848–1851. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bienz M, Ludwig M, Leibundgut EO, Mueller
BU, Ratschiller D, Solenthaler M, Fey MF and Pabst T: Risk
assessment in patients with acute myeloid leukemia and a normal
karyotype. Clin Cancer Res. 11:1416–1424. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Medeiros BC, Gotlib J and Zehnder J:
Molecular stratification of patients with normal karyotype acute
myeloid leukemia based on initial assessment of FLT3-internal
tandem duplication status at first complete remission. Leuk
Lymphoma. 50:851–853. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Medeiros BC: Role of CEBPA in normal
karyotype acute myeloid leukemia. J Clin Oncol. 27:21052009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yoshimoto G, Nagafuji K, Miyamoto T,
Kinukawa N, Takase K, Eto T, Kato K, Hayashi S, Kamimura T, Ohno Y,
et al: FLT3 mutations in normal karyotype acute myeloid leukemia in
first complete remission treated with autologous peripheral blood
stem cell transplantation. Bone Marrow Transplant. 36:977–983.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Foran JM: New prognostic markers in acute
myeloid leukemia: Perspective from the clinic. Hematology Am Soc
Hematol Educ Program. 2010:47–55. 2010.PubMed/NCBI
|
|
34
|
Kadia T, Kantarjian H, Garcia-Manero G,
Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N,
Pemmaraju N, et al: Prognostic significance of the medical research
council cytogenetic classification compared with the European
LeukemiaNet risk classification system in acute myeloid leukemia.
Br J Hematol. 170:590–593. 2015. View Article : Google Scholar
|
